{"article_link": "https://doi.org/10.1038/s41467-023-42565-z", "data": [{"id": "data_1", "omics": "Epigenomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA002815"}, {"id": "data_2", "omics": "Transcriptomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "Processed Data", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA000119"}, {"id": "data_3", "omics": "Genomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "Processed Data", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA005668"}, {"id": "data_4", "omics": "ChIP-seq", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122989", "format": "Processed Data", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE122989"}, {"id": "data_5", "omics": "ChIP-seq", "link": "https://ega-archive.org/", "format": "Processed Data", "source": "European Genome-phenome Archive (EGA)", "public_id": "EGAD00001002421"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://depmap.org/portal/download", "format": "Processed Data", "source": "DepMap", "public_id": "DepMap Public 21Q1"}, {"id": "data_7", "omics": "Drug Response", "link": "https://depmap.org/portal/download", "format": "Processed Data", "source": "DepMap", "public_id": "Drug sensitivity AUC (CTD^2)"}, {"id": "data_8", "omics": "Genomics", "link": "https://gdc.cancer.gov/about-data/publications#/?groups=TARGET-ALL-P2&years=&order=desc", "format": "Processed Data", "source": "TARGET", "public_id": "phs000464"}, {"id": "data_9", "omics": "Epigenomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "Processed Data", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "758,738 c-ACRs"}], "analyses": [{"id": "analysis_1", "analysis_type": "ATAC-seq", "analysis_data": ["data_1"], "training_set": [], "test_set": [], "label": {}}, {"id": "analysis_2", "analysis_type": "comparison", "analysis_data": ["data_1", "data_4"], "training_set": [], "test_set": [], "label": {"cell_type": ["B-ALL", "B-cell progenitor"]}}, {"id": "analysis_3", "analysis_type": "subtyping", "analysis_data": ["data_1"], "training_set": [], "test_set": [], "label": {"subtypes": ["ETV6::RUNX1", "Hyperdiploidy", "KMT2A", "BCR::ABL1"]}}, {"id": "analysis_4", "analysis_type": "allele-specific analysis", "analysis_data": ["data_1", "data_3"], "training_set": [], "test_set": [], "label": {"allele_status": ["ASOC", "BiOC"]}}, {"id": "analysis_5", "analysis_type": "differential analysis", "analysis_data": ["data_1"], "training_set": [], "test_set": [], "label": {"condition": ["diagnosis", "relapse"]}}, {"id": "analysis_6", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": [], "test_set": [], "label": {"outcome": ["relapse-free survival"]}}, {"id": "analysis_7", "analysis_type": "ACR-gene association", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {}}, {"id": "analysis_8", "analysis_type": "enrichment analysis", "analysis_data": ["data_6", "data_7"], "training_set": [], "test_set": [], "label": {"drug": ["Imatinib", "Etoposide"]}}, {"id": "analysis_9", "analysis_type": "motif analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"factor_type": ["transcription_factor"]}}, {"id": "analysis_10", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": [], "test_set": [], "label": {"cluster": ["Group A", "Group B"]}}], "results": [{"analysis_id": "analysis_1", "metric": "Number of ACRs", "value": "138,366 (median), ranging from 57,941 to 204,563", "features": ["ACRs in Quies regions", "ACRs in Enh regions", "ACRs in TssA regions", "ACRs in Tx regions"]}, {"analysis_id": "analysis_2", "metric": "Overlap Percentage", "value": "98.57% (pre-pro B cells), 98.35% (pro B cells)", "features": ["IL7R", "TCL1A", "TCF3", "RHOA", "ELL", "MYC"]}, {"analysis_id": "analysis_3", "metric": "Number of Subtype-specific ACRs", "value": "17,981 subtype-specific ACRs identified", "features": ["ACRs in ETV6::RUNX1", "ACRs in Hyperdiploidy", "ACRs in KMT2A"]}, {"analysis_id": "analysis_4", "metric": "Percentage of ASOC Regions", "value": "14.39% (median), significantly less than BiOC regions (85.61%)", "features": ["ACR: rs7090445", "ACR: rs13401811", "ARID5B", "BCL2L11", "MECOM", "HOXA9"]}, {"analysis_id": "analysis_5", "metric": "Number of Differential ACRs", "value": "5911 relapse-high ACRs (0.95%), 1423 relapse-low ACRs (0.23%)", "features": ["Cyclophosphamide", "Cytarabine", "Dasatinib", "Dexamethasone", "Doxorubicin", "Etoposide", "Imatinib", "Methotrexate"]}, {"analysis_id": "analysis_6", "metric": "Shared vs. Subtype-specific ACRs", "value": "1.54% (relapse-high ACRs), 0.14% (relapse-low ACRs) shared between subtypes", "features": ["ETV6::RUNX1", "Hyperdiploidy", "KMT2A", "BCR::ABL1", "BCR::ABL1-like", "TCF3::PBX1"]}, {"analysis_id": "analysis_7", "metric": "ACR-gene Correlations", "value": "116,307 ACR-gene correlations identified", "features": ["1259 potential target genes", "Cell adhesion-related biological processes", "Drug response genes"]}, {"analysis_id": "analysis_8", "metric": "Enrichment in Drug Response Genes", "value": "Significant enrichment for Imatinib (p = 0.0029), Etoposide (p = 0.0184), Dasatinib (p = 0.0178), Doxorubicin (p = 0.0167)", "features": ["Imatinib", "Etoposide", "Dasatinib", "Doxorubicin"]}, {"analysis_id": "analysis_9", "metric": "Transcription Factor Enrichment", "value": "109 TFs associated with subtype-specific ACRs", "features": ["E2F6", "RUNX1", "ZFP82", "SPI1", "KLF9", "NRF1", "RARG", "SALL4", "CTCF"]}, {"analysis_id": "analysis_10", "metric": "Survival Difference", "value": "Significant differences in EFS and OS between clusters (p = 0.0012 and p = 0.0002 respectively)", "features": ["Cluster 3 (worst prognosis)", "Hyperdiploidy cases in Group B", "ETV6::RUNX1", "KMT2A", "BCR::ABL1-like"]}, {"analysis_id": "analysis_1", "metric": "Cohort-level ACRs", "value": "758,738 c-ACRs identified", "features": ["Quies regions (27.95% median)", "Enh regions (31.30% median)", "TssA regions (20.38% median)"]}]}